Deals30 Aug 2024, 04:57 pm
Thyrocare Technologies Ltd to Acquire Diagnostic Business of Vimta Labs Limited for Slump Sale
AI Summary
Thyrocare Technologies Ltd has entered into a Business Transfer Agreement (BTA) with Vimta Labs Limited to acquire its diagnostic and pathological services business on a slump sale basis. The acquisition is subject to the fulfillment of certain conditions precedent. Through this acquisition, Thyrocare aims to expand its diagnostic and pathological services business, aligning with its growth objectives and strengthening its market position in South India. This strategic move will also enable Thyrocare to leverage the benefits of scale.
Key Highlights
- Thyrocare Technologies Ltd has signed a BTA with Vimta Labs Limited for the acquisition of its diagnostic and pathological services business.
- The acquisition is a slump sale of Vimta's diagnostic business, which is subject to fulfillment of certain conditions precedent.
- Thyrocare's acquisition aims to expand its diagnostic and pathological services business and strengthen its market position in South India.
- This strategic move will allow Thyrocare to leverage the benefits of scale in its operations.
- The acquisition does not fall under related party transactions and there is no promoter/promoter group/group companies' interest involved.